Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Value of biomarkers in urology].

Literature DB >> 20376654

[Value of biomarkers in urology].

P J Goebell¹, B Keck, S Wach, B Wullich.

Abstract

As part of the diagnosis and treatment of cancer objective biological measures are becoming increasingly important and may help to elicit the individual patient's risk of future outcome. Among theses measures are markers as determinants for the biological potential of the malignant disease, the prediction of recurrence after systemic treatment or the response to a specific therapy. In counselling patients with uro-oncologic diseases, the emerging role of evidence-based treatment choices reveals with cumulative certainty that the available information on markers is inconclusive.The aim of this review is to provide a summary of the current evidence of the evaluation of markers, which may be supportive for a treatment decision and/or provide additional valuable information as part of the treatment option. In addition, this may provide access to some of the most promising investigations, which may yield perspectives for future relevant clinical questions.

Entities: Disease Species

Mesh：

Substances：

Year: 2010 PMID： 20376654 DOI： 10.1007/s00120-010-2286-8

Source DB: PubMed Journal: Urologe A ISSN： 0340-2592 Impact factor: 0.639

187 in total

1. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.

Authors: Vinata B Lokeshwar; Tomonori Habuchi; H Barton Grossman; William M Murphy; Stefan H Hautmann; George P Hemstreet; Aldo V Bono; Robert H Getzenberg; Peter Goebell; Bernd J Schmitz-Dräger; Jack A Schalken; Yves Fradet; Michael Marberger; Edward Messing; Michael J Droller
Journal: Urology Date: 2005-12 Impact factor: 2.649

2. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.

Authors: P Mhawech-Fauceglia; R T Cheney; G Fischer; A Beck; F R Herrmann
Journal: Eur J Surg Oncol Date: 2006-01-18 Impact factor: 4.424

3. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin.

Authors: W M Zhang; P Finne; J Leinonen; S Vesalainen; S Nordling; S Rannikko; U H Stenman
Journal: Clin Chem Date: 1998-12 Impact factor: 8.327

4. In mouse alpha -methylacyl-CoA racemase, the same gene product is simultaneously located in mitochondria and peroxisomes.

Authors: T J Kotti; K Savolainen; H M Helander; A Yagi; D K Novikov; N Kalkkinen; E Conzelmann; J K Hiltunen; W Schmitz
Journal: J Biol Chem Date: 2000-07-07 Impact factor: 5.157

5. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.

Authors: Ken Kawamoto; Hideki Enokida; Takenari Gotanda; Hiroyuki Kubo; Kenryu Nishiyama; Motoshi Kawahara; Masayuki Nakagawa
Journal: Biochem Biophys Res Commun Date: 2005-11-22 Impact factor: 3.575

6. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

Authors: Adel H Jebar; Carolyn D Hurst; Darren C Tomlinson; Colin Johnston; Claire F Taylor; Margaret A Knowles
Journal: Oncogene Date: 2005-08-04 Impact factor: 9.867

7. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.

Authors: Xi Na; Guan Wu; Charlotte K Ryan; Susan R Schoen; P Anthony di'Santagnese; Edward M Messing
Journal: J Urol Date: 2003-08 Impact factor: 7.450

3. Hydronephrosis due to pelviureteric junction narrowing: Utility of urinary enzymes to predict the need for surgical management and follow-up.

Authors: Kirtikumar J Rathod; Ram Samujh; Sumeet Agarwal; Ravi Prakash Kanojia; Ujjawal Sharma; Rajendra Prasad
Journal: J Indian Assoc Pediatr Surg Date: 2012-01

3 in total

[Value of biomarkers in urology].

1. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.

2. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.

3. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin.

4. In mouse alpha -methylacyl-CoA racemase, the same gene product is simultaneously located in mitochondria and peroxisomes.

5. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.

6. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

7. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.

8. Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.

9. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.

10. A population-based study of immunohistochemical detection of p53 alteration in bladder cancer.

1. [Circulating cell-free serum DNA: significance as a new biomarker for urological malignancies].

2. [Plasma E-cadherin levels in urinary bladder cancer: does it improve risk stratification?].

3. Hydronephrosis due to pelviureteric junction narrowing: Utility of urinary enzymes to predict the need for surgical management and follow-up.